Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2007

View Archived Issues

Neuren to acquire Hamilton

TargeGen begins phase II trial of TG-100801 eye drops for AMD

Positive results for Novogen's antiinflammatory FAIMs in preclinical studies

Lexicon completes phase I trials of LX-6171 for cognitive disorders

AVEO's oral antiangiogenic agent heads for phase II evaluation in RCC

Phase II study data on vicriviroc presented

Sanofi-aventis and Chugai marketing collaboration in Japan terminated

New treatment options for cardiovascular diseases discussed in recent patent literature

New compounds for the treatment of neurological disorders claimed in recent patents

New antiarthritic drugs claimed in recent patent literature

Positive interim results from AlphaVax's phase I influenza vaccine trial

Astion's ASF-1096 recommended orphan drug status by EMEA

Kyowa Hakko receives MHLW approval for antiepileptic agent KW-6485

Banyu receives MHLW approval for Singulair fine granule 4 mg for infant bronchial asthma

Incyte reports second quarter 2007 results

FDA accepts Fentanyl MDTS IND from Acrux; phase I trial to begin

Poniard begins phase II trial of intravenous picoplatin with Taxotere and prednisone

Javelin begins phase III trial of intranasal ketamine for breakthrough cancer pain

Phase II trial of trastuzumab-DM1 begins; ImmunoGen receives milestone payment

AlphaVax proceeds with the development of a smallpox vaccine

Inactivated whole-virion SARS vaccine immunogenic and protective in hamster model

Erythropoietin modulates emotional responses in humans

Accentia submits pre-IND application for Revimmune

YM begins enrollment of phase II trial of nimotuzumab for colorectal cancer

Positive interim results for OncoGenex and Isis' phase II OGX-011 trial

Antigenics applies for Oncophage approval for kidney cancer in Russia

Second FDA approvable letter issued for Trexima

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...